Remove tag disability
article thumbnail

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US

Pharmaceutical Technology

Multiple sclerosis (MS) is a primary autoimmune disease in which inflammation is a core contributor to the degeneration of the central nervous system (CNS), leading to neurological disability and affecting sensory, visual, motor, and autonomic systems. DMTs for MS have a high price tag, particularly in the US.

Marketing 246
article thumbnail

Jolly Good/Teijin Pharma develop VR digital therapeutics for depression

pharmaphorum

Using technologies such as VR and AI, the company aims to accelerate human growth and social rehabilitation in medical education and provide support for people with disabilities, as well as provide treatments for mental illness. The post Jolly Good/Teijin Pharma develop VR digital therapeutics for depression appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds January 12, 2024: Design and Implementation of a Weighted Lottery to Equitably Allocate Scarce Covid-19 Resources (Erin K. McCreary, PharmD, BCIDP)

Rethinking Clinical Trials

Tags #pctGR, @Collaboratory1 The post Grand Rounds January 12, 2024: Design and Implementation of a Weighted Lottery to Equitably Allocate Scarce Covid-19 Resources (Erin K. We know there is a digital gap in disadvantaged patients and elderly patients. Many patients did not answer the phone.

article thumbnail

AI-designed protein awakens silenced genes, one by one

The Pharma Data

By combining CRISPR technology with a protein designed with artificial intelligence (AI), it is possible to awaken individual dormant genes by disabling the chemical “off switches” that silence them. Ruohola-Baker and Levy then fused this designed protein with a disabled version of a protein called Cas9.

Protein 52
article thumbnail

NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta

pharmaphorum

NICE’s final appraisal document for Kesimpta will be followed by technology appraisal guidance (TAG) that will pave the way for NHS prescribing in England and Wales. The Scottish Medicines Consortium is expected to publish its final advice on the drug later this year.

Sales 111
article thumbnail

Sarepta’s Elevidys Reaches Finish Line as First Gene Therapy Approved for Duchenne Muscular Dystrophy

XTalks

Symptoms of DMD can include difficulties walking and running, falling frequently, fatigue, learning disabilities/difficulties, heart issues and breathing problems. million price tag of Elevidys, a one-time gene therapy. DMD is caused by the absence of dystrophin, a protein that helps maintain the integrity of muscle cells.

article thumbnail

Lyfgenia and Casgevy Become First FDA-Approved Gene Therapies for Sickle Cell Disease

XTalks

The recurrence of these events, or crises, can lead to life-threatening disabilities and/or early death. The sickled red blood cells obstruct flow in blood vessels, limiting oxygen delivery to tissues in the body, which leads to severe pain and organ damage called vaso-occlusive events (VOEs) or vaso-occlusive crises (VOCs).